British Journal of Pharmacology · 2001 · 197 citations · 22 references
MedicineBiochemistryPharmacologyBiochemical PharmacologyDrug MetabolismMetabolismCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug-metabolizing EnzymesEnzyme InhibitionRenal PharmacologyArachidonic Acid MetabolitesCytochrome P450 Enzyme ActivityCytochrome P450 Enzyme InhibitionCytochrome P450 InhibitionCytochrome P450 Metabolic PathwaysCytochrome P450 OxidationMetabolic Enzyme InhibitionRenal Metabolism
The present study examined the inhibitory effects of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016) on the renal metabolism of arachidonic acid by cytochrome P450 (CYP) enzymes. HET0016 exhibited a high degree of selectivity in inhibiting the formation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) in rat renal microsomes. The IC(50) value averaged 35+/-4 nM, whereas the IC(50) value for inhibition of the formation of epoxyeicosatrienoic acids by HET0016 averaged 2800+/-300 nM. In human renal microsomes, HET0016 potently inhibited the formation of 20-HETE with an IC(50) value of 8.9+/-2.7 nM. Higher concentrations of HET0016 also inhibited the CYP2C9, CYP2D6 and CYP3A4-catalysed substrates oxidation with IC(50) values of 3300, 83,900 and 71,000 nM. The IC(50) value for HET0016 on cyclo-oxygenase activity was 2300 nM. These results indicate that HET0016 is a potent and selective inhibitor of CYP enzymes responsible for the formation of 20-HETE in man and rat.
22
Production of 20-HETE and Its Role in Autoregulation of Cerebral Blood Flow
Debebe Gebremedhin, Andrew R. Lange, T. F. Lowry et al. · Circulation Research · 2000 · 317 citations
Medicine, Pharmacology, Physiology +16
Mong-Heng Wang, Elimor Brand‐Schieber, Barbara A. Zand et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 232 citations